Researchers used the Parsortix ® system to isolate and harvest CTCs from 30 patients with EGFR-mutated NSCLC that were undergoing treatment with osimertinib (TAGRISSO: AstraZeneca). Osimertinib is an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback